ReviewBMC infectious diseases2026
Robinsoniella peoriensis bacteremia in a patient with colorectal cancer: a case report and literature review.
Review in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRobinsoniella peoriensis, an anaerobic, Gram-positive bacillus within the phylum Firmicutes and family Lachnospiraceae, is a putative commensal anaerobe of the human gut and an infrequent cause of opportunistic infection, including severe bloodstream infections (BSI). We report a case of BSI due to R. peoriensis and analyze its pertinent clinical and microbiological characteristics. CASE PRESENTATION: The patient was a 71-year-old male who developed BSI secondary to anastomotic leakage following laparoscopic radical resection for rectal adenocarcinoma. Anaerobic blood cultures obtained on postoperative day 4 signaled positive after 96 h of incubation. The isolate was identified as R. peoriensis by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). Whole-genome sequencing revealed a notably diverse array of antimicrobial resistance genes, as well as two virulence-associated genes (tufA and groEL). Etest-based antimicrobial susceptibility testing demonstrated susceptibility to vancomycin, piperacillin-tazobactam, meropenem, and imipenem; intermediate resistant to clindamycin; and resistant to penicillin. The infection was effectively controlled after clinicians promptly initiated empirical therapy with meropenem monotherapy, and the patient eventually recovered and was discharged.
conclusionThis case highlights that R. peoriensis infection can be associated with disruption of the intestinal mucosal barrier, as may occur following surgery for malignancy. A marked discordance between the genotypic resistance profile and phenotypic susceptibility was observed, emphasizing the critical role of standardized in vitro susceptibility testing to guide therapy. Carbapenems (e.g., meropenem) represent an effective therapeutic option for such infections. Due to the rarity of Robinsoniella peoriensis infections, our literature review identified only 22 previously documented cases, we aim to provide insights to aid in the diagnosis and treatment of infections caused by this rare pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.